TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00235716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: A moderate-affinity NMDA antagonist. Memantine will be titrated over four weeks to a maintenance dose of 10 mg twice a day. During week 1 patients will take one 5-mg memantine tablet in the morning. During week 2 patients will take one 5-mg memantine tablet in the morning and one in the evening. During week 3 patients will take two 5-mg memantine tablets in the morning and one 5-mg tablet in the evening. Beginning with week 4, participants will take four 5-mg tablets daily, two in the morning and two in the evening.
Study: NCT03651960

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ROBOT PROTOTYPE
Description: The intervention consists of 12 45-minute sessions of balance and gait training with a mobile and interactive robot prototype for 4 weeks.
Study: NCT04169620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aquatic Ai Chi
Description: The sessions took place in a pool measuring 20 m x 6 m, at a depth of 110 cm. The water temperature was 30oC (with variations of less than 0.5o) and the room temperature was 27.5oC (with variations of less than 1o). The proportions of the pool were ideally suited for collective treatment.~The sessions were designed with a gradual increase in difficulty. Initially, a recreational warm-up activity was performed, followed by 30 minutes dedicated to practicing the Ai Chi Program. At the end of the session there was a calming down activity. The exercises were performed in a specific order, until completion of the 19 possible movements.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: These sessions consisted of group sessions of supervised training lasting 45 minutes each. These comprised a 10-minute warm-up that included exercises for gait, trunk mobility and exercises involving the upper and lower limbs. The central part of the sessions consisted of 30-40 minutes of strength training and aerobic exercises, both individual and in groups. Each session was performed with a specific intensity goal, in order to end with a cooling down period, comprising 20 minutes of functional exercises based on activities of daily living, balance exercises, facial muscle exercises, proprioceptive exercises, muscle relaxation and stretching.
Study: NCT00453349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (Avelox, BAY12-8039)
Description: Moxifloxacin (Avelox, BAY12-8039) 400 mg by mouth (PO) once daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin & Metronidazole
Description: Levofloxacin 500 mg by mouth (PO) once daily for 14 days plus Metronidazole 500 mg (PO) twice daily for 14 days
Study: NCT01365195

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Loading and Infusion: Saline at infusion rate calculated and adjusted for weight to match ketamine bolus-infusion rate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Loading and Infusion: Saline at infusion rate calculated and adjusted for weight to match ketamine bolus-infusion rate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine high-dose
Description: Loading: 1 mg/Kg Infusion: 10 mcg/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine high-dose
Description: Loading: 1 mg/Kg Infusion: 10 mcg/kg/min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine low-dose
Description: Loading: 0.5 mg/Kg Infusion: 5 mcg/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine low-dose
Description: Loading: 0.5 mg/Kg Infusion: 5 mcg/kg/min
Study: NCT02391649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-learning program
Description: The PSBBP in this study consists of 5 modules (Module 1: Caregiver's well-being; Module 2:Getting the best out of support services; Module 3:Well-being of the person with schizophrenia; Module 4:Dealing with the \[psychosocial\] effects of the illness; and Module 5:Dealing with \[physical and mental health\] effects of the illness), helping each caregiver from developing a positive attitude to caregiving, identifying caring related problems and obstacles, predicting positive and negative implications of each alternative, to trying out the solution and monitor if it worked.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-education program (in Phase 2)
Description: The program consists of 12 two-hour sessions held weekly/biweekly completed in 5 months, with 4 main components, including 'introduction and goal setting'; 'an education workshop on mental illness, treatment and community services'; 'group exercises/rehearsals and discussion on symptom management, coping and self-care'; and 'review and future plan'.
Study: NCT00902122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAd-p53 gene
Description: pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 5 times

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: removal of thyroid tumor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: p53 gene therapy
Description: p53 gene treatment: 10exp12 virus particles per 3 days for 10 times

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: p53 gene therapy with radioactive iodine
Description: p53 gene therapy with concurrent radioactive iodine pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
Study: NCT02090140

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ADSC Application
Description: Patients will undergo arthroscopic resection of approximately 5cc of the infrapatellar fat pad, which will be collected for processing for a population of ADSCs. Patients will undergo arthroscopy and preparation of the chondral defect and removal of the calcified cartilage layer. Tisseel Fibrin glue will be placed at the base of the defect side, followed by the application of the acellular collagen dermal matrix, ADSCs, and an additional layer of fibrin glue.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: Microfracture surgery is the standard of care for articular cartilage lesions. Patients will undergo arthroscopy with standard technique of microfracture preparation, including the creation of vertical, stable defect edges and removal of the calcified cartilage layer. A microfracture awl will then be used to perform the microfracture technique (6mm below the subchondral plate).
Study: NCT03060109

Intervention type: OTHER
Intervention: Blood draw within 12 hours of injury
Study: NCT00235716

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebos for dl-alpha-tocopherol and memantine.
Study: NCT03036189

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: baa nnilah
Description: 7 meetings in the community led by a trained community facilitator

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: baa nnilah
Description: 7 meetings in the community led by a trained community facilitator
Study: NCT04022655

Intervention type: OTHER
Intervention: ICU Care
Description: No intervention
Study: NCT01204216

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: re-infusion of biotin labeled cells
Description: Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (\< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.~These experiments require a series of small, precisely timed post-infusion blood samples over a period of 4 months, with each subject undergoing the procedure twice separated by an interval of at least 8 month

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Re-infusion of biotin labeled cells
Description: Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (\< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.~These experiments require a series of small, precisely timed post-infusion blood samples over a period of 4 months, with each subject undergoing the procedure twice separated by an interval of at least 8 months.~small volume (\< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes education/diabetes medication adjustment
Description: Between the initial 3-4 month trial period and the second infusion of biotin labeled cells approximately 8 months later,subjects will receive diabetes education from a CDE. In addition,if needed, diabetes medications may be adjusted by the study endocrinologist to improve subject's glycemic control.
Study: NCT03546088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fiberoptic naso-tracheal intubation
Description: The trachea will be intubated under direct fiberoptic view after a fiberoptic upper airway examination. The flexible nasolaryngoscope will be armed with an intubating tube and passed inside tracheal lumen trough one of the nostrils.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical anaesthesia
Description: Topical anaesthesia with lidocaine will be provided through nebulisation and instillation. The intubating tube will be lubricated with a gel containing lidocaine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Light sedation
Description: The patient will be sedated with a combination of midazolam, fentanyl administered intravenously in small boluses until the desired level of sedation is achieved as expressed of The Observer's Assessment of Alertness/Sedation Scale (OAA/S) of 4 or 5.
Study: NCT01810315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TFV 1% gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TFV 1% gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol vaginal cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol vaginal cream
Study: NCT02249182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF FDC administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF FDC administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF FDC administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) oral solution or capsules will be administered orally in a divided daily dose based on weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) oral solution or capsules will be administered orally in a divided daily dose based on weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) oral solution or capsules will be administered orally in a divided daily dose based on weight
Study: NCT01835834

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: zirconia bridge restoration
Study: NCT01497782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instructor feedback
Description: Intervention group who receives up to three sessions of instructor feedback during completion of a predefined proficiency level on a laparoscopic virtual reality simulator.
Study: NCT04510532

Intervention type: DIAGNOSTIC_TEST
Intervention: CMR examination
Description: After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on .And the follow-up is planned at 1,6 months after chemotherapy in order to detect the cardiac impairment

Intervention type: DIAGNOSTIC_TEST
Intervention: CMR examination
Description: After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on .And the follow-up is planned at 1,6 months after chemotherapy in order to detect the cardiac impairment

Intervention type: DIAGNOSTIC_TEST
Intervention: CMR examination
Description: After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on .And the follow-up is planned at 1,6 months after chemotherapy in order to detect the cardiac impairment
Study: NCT03815825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS-FB-LRx
Description: IONIS-FB-LRx at multiple ascending doses, administered subcutaneously every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching solution, administered subcutaneously every 4 weeks
Study: NCT03310749

Intervention type: DRUG
Group type: OTHER
Intervention: Gemigliptin
Description: A 7-day treatment period with gemigliptin 50 mg q.d., followed by a 5-day washout period; a 7 day treatment period with metformin 1000 mg twice a day followed by a 5-day washout period and a final 7-day treatment period with gemigliptin 50 mg q.d. + metformin 1000 mg twice a day

Intervention type: DRUG
Group type: OTHER
Intervention: Gemigliptin
Description: A 7-day treatment period with gemigliptin 50 mg q.d., followed by a 5-day washout period; a 7 day treatment period with metformin 1000 mg twice a day followed by a 5-day washout period and a final 7-day treatment period with gemigliptin 50 mg q.d. + metformin 1000 mg twice a day
Study: NCT02537184

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Oral Clinical conditions
Description: caries incidence assessment dental anxiety assessment

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Oral Clinical conditions
Description: caries incidence assessment dental anxiety assessment
Study: NCT02592460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: poor-polyamines diet
Description: Patients in this will receive a poor-polyamines diet during a week before and a week after foot surgery
Study: NCT02945176

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARGOS-IO system
Description: This study will enroll a minimum of 10 and a maximum of 15 patients. It is anticipated to be large enough to provide an initial estimate of common safety events and assessment of performance. Any adverse event (AE), serious adverse event (SAE), ADE (adverse device event) and SADE (serious adverse device event) will be listed. Incidence will be estimated with a 95% confidence interval (Pearson-Clopper, two-sided). The Bland-Altman method will be used to assess the limits of agreement between the IOP measurements ARGOS-IO and surgical manometry. When appropriate, two-sided 95% confidence intervals, for these limits will be calculated accounting for repeated measurements based on the method proposed by Zou (2011). Other secondary performance endpoints will be analyzed by descriptive and explorative statistical methods.
Study: NCT00139828

Intervention type: DRUG
Group type: OTHER
Intervention: human coagulation Factor IX
Study: NCT02592460

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high polyamines diet
Description: Patients in this will receive a high-polyamines diet during a week before and a week after foot surgery
Study: NCT00398320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 850 mg/m2 by mouth twice a day for days 1-14 oa a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2 intravenously on day 1 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5mg/kg Intravenous on day 1 of a 21 day cycle
Study: NCT01816802

Intervention type: DEVICE
Intervention: In-vitro fertilization using Eeva
Description: Eeva will image embryos through cleavage stage (Day 3). Embryologists will use Eeva results along with traditional morphological grading to assist in selecting embryo(s) for transfer or freezing.
Study: NCT01496820

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GO2KA1
Description: GO2KA1(chitosan oligosaccharide)1500mg/day for 12weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 1500mg/day for 12weeks
Study: NCT01002274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCS-2
Description: 2 soft-gel capsules Qd for 40 weeks
Study: NCT02678923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDCO-216

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03312426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: Single dose, 100 mg administered at Day 1 and at Day 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: Single dose, 100 mg administered at Day 1 and at Day 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: Single dose, 100 mg administered at Day 1 and at Day 15.
Study: NCT03022760

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Work-related measures
Description: After mapping the patient's psychosocial work situation using tools provided at the one-day training, the patient's employer will be contacted and involved in the rehabilitation planning.
Study: NCT01464346

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enlite Sensor
Description: This is the Enlite sensor (all subjects)
Study: NCT03312426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: Single dose, 100 mg administered at Day 1 and at Day 15.
Study: NCT04218591

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PRP
Description: Platelet rich plasma

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT03688620

Intervention type: OTHER
Group type: OTHER
Intervention: Passive enhanced safety surveillance
Description: Prospective data collection starting at Visit 1 (Day 1) and ending at Visit 2 (Day 8 or when the ADR card was returned by mail) for all subjects who have previously been vaccinated against influenza in preceding seasons or aged ≥9 years at the time of vaccination, or ending at Visit 4 (Day 36 or when the last ADR card was returned by mail) for children aged \<9 years who have not previously been vaccinated against influenza in preceding seasons). Subjects had up to 14 days post vaccination to return their ADR card (at the next study visit or by mail).

Intervention type: OTHER
Group type: OTHER
Intervention: Passive enhanced safety surveillance
Description: Prospective data collection starting at Visit 1 (Day 1) and ending at Visit 2 (Day 8 or when the ADR card was returned by mail) for all subjects who have previously been vaccinated against influenza in preceding seasons or aged ≥9 years at the time of vaccination, or ending at Visit 4 (Day 36 or when the last ADR card was returned by mail) for children aged \<9 years who have not previously been vaccinated against influenza in preceding seasons). Subjects had up to 14 days post vaccination to return their ADR card (at the next study visit or by mail).

Intervention type: OTHER
Group type: OTHER
Intervention: Passive enhanced safety surveillance
Description: Prospective data collection starting at Visit 1 (Day 1) and ending at Visit 2 (Day 8 or when the ADR card was returned by mail) for all subjects who have previously been vaccinated against influenza in preceding seasons or aged ≥9 years at the time of vaccination, or ending at Visit 4 (Day 36 or when the last ADR card was returned by mail) for children aged \<9 years who have not previously been vaccinated against influenza in preceding seasons). Subjects had up to 14 days post vaccination to return their ADR card (at the next study visit or by mail).
Study: NCT03046030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Description: Verum acupuncture will be applied on the right SP6 and SP9. For each subject, leg position, acupoint location, and needling parameters (1-2 cm depth, 120 rotations / minute, 90˚ insertion angle, moderate deqi sensations on a 0-10 scale) will be kept constant. For the low dose acupuncture group, needles will be rotated at one point and then the other in 15-second rotations with 20-30 second breaks. The specific starting acupoint will be randomized across subjects but kept consistent for each subject across sessions.
Study: NCT01464346

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enlite Sensor
Description: This is the Enlite sensor (all subjects)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enlite Sensor
Description: This is the Enlite sensor (all subjects)
Study: NCT03810274

Intervention type: DEVICE
Intervention: 3DV+TPS；VARIAN TPS；FonicsPlan
Study: NCT03046030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham acupuncture
Description: Placebo acupuncture will be applied at two sham points using specially designed sham acupuncture needles \[20, 35, 104-106\]. The sham needles differ from regular needles by possessing blunt and retractable tips. Instead of penetrating the skin, the point of the Streitberger needle retracts up the handle shaft when the acupuncturist presses it against the skin. This sham device has been validated by studies showing that subjects cannot distinguish between genuine and sham needling \[20, 35, 104\]. Two sham points will be used during placebo acupuncture: sham point 1 is located 1 cun posterior to the superior 1/3 of K9 and K10. Sham 2 is located 1 cun posterior to K8. Both points are located on the leg where there is no meridian passing through. Sham acupuncture treatment will be the same as verum acupuncture.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VGAIT
Description: In Session 1, all patients will first be introduced to acupuncture treatment, particularly the sensation evoked by acupuncture needles. This will be followed by a five-minute acupuncture exposure applied by a licensed acupuncturist. The exposure will include multiple acupuncture needle manipulations across the two acupoints (SP 6 and SP 9) used in this study. The paradigm applied will be identical to real acupuncture treatment, and the procedure will also be video recorded for the following session. At the beginning of the VGAIT session, patients will be trained for imagery acupuncture outside the fMRI scan. Subjects will first read a script introducing the imagery acupuncture treatment. Then, VGAIT will be applied during scanning. Identical to the acupuncture treatment, there are two fMRI scans during VGAIT, each lasting about 10 minutes. We will ask the patient to measure the sensations they feel during treatment using the MGH Acupuncture Sensation Scale (MASS) after treatment.
Study: NCT03049839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention_ S
Description: One year Structured intervention program for members of high-risk group (Subjects with FINDRISC score ≥12 points and impaired glucose tolerance (IGT))
Study: NCT03046030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VGAIT control
Description: The control condition will be the same as VGAIT, except we will use cotton swabs repeatedly touching at non-acupoints with a frequency of about 1 Hz using the same paradigm of verum / sham acupuncture. They will also read a script describing what they are about to see. Then, VGAIT control will be applied during scanning. We will ask the patient to measure the sensations they feel during treatment using the MASS after treatment.